Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160332462> ?p ?o ?g. }
- W3160332462 abstract "Abstract Background In the first wave of the COVID-19 pandemic, the hypothesis that angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) increased the risk and/or severity of the disease was widely spread. Consequently, in many hospitals, these drugs were discontinued as a “precautionary measure”. We aimed to assess whether the in-hospital discontinuation of ARBs or ACEIs, in real-life conditions, was associated with a reduced risk of death as compared to their continuation and also to compare head-to-head the continuation of ARBs with the continuation of ACEIs. Methods Adult patients with a PCR-confirmed diagnosis of COVID-19 requiring admission during March 2020 were consecutively selected from 7 hospitals in Madrid, Spain. Among them, we identified outpatient users of ACEIs/ARBs and divided them in two cohorts depending on treatment discontinuation/continuation at admission. Then, they were followed-up until discharge or in-hospital death. An intention-to-treat survival analysis was carried out and hazard ratios (HRs), and their 95%CIs were computed through a Cox regression model adjusted for propensity scores of discontinuation and controlled by potential mediators. Results Out of 625 ACEI/ARB users, 340 (54.4%) discontinued treatment. The in-hospital mortality rates were 27.6% and 27.7% in discontinuation and continuation cohorts, respectively (HR=1.01; 95%CI 0.70–1.46). No difference in mortality was observed between ARB and ACEI discontinuation (28.6% vs. 27.1%, respectively), while a significantly lower mortality rate was found among patients who continued with ARBs (20.8%, N =125) as compared to those who continued with ACEIs (33.1%, N =136; p =0.03). The head-to-head comparison (ARB vs. ACEI continuation) yielded an adjusted HR of 0.52 (95%CI 0.29–0.93), being especially notorious among males (HR=0.34; 95%CI 0.12–0.93), subjects older than 74 years (HR=0.46; 95%CI 0.25–0.85), and patients with obesity (HR=0.22; 95%CI 0.05–0.94), diabetes (HR=0.36; 95%CI 0.13–0.97), and heart failure (HR=0.12; 95%CI 0.03–0.97). Conclusions The discontinuation of ACEIs/ARBs at admission did not improve the in-hospital survival. On the contrary, the continuation with ARBs was associated with a trend to a reduced mortality as compared to their discontinuation and to a significantly lower mortality risk as compared to the continuation with ACEIs, particularly in high-risk patients." @default.
- W3160332462 created "2021-05-24" @default.
- W3160332462 creator A5000143586 @default.
- W3160332462 creator A5001965211 @default.
- W3160332462 creator A5004792362 @default.
- W3160332462 creator A5008912002 @default.
- W3160332462 creator A5010358276 @default.
- W3160332462 creator A5012387973 @default.
- W3160332462 creator A5013366022 @default.
- W3160332462 creator A5019430299 @default.
- W3160332462 creator A5021414030 @default.
- W3160332462 creator A5021832421 @default.
- W3160332462 creator A5022630756 @default.
- W3160332462 creator A5024457860 @default.
- W3160332462 creator A5026681178 @default.
- W3160332462 creator A5030324301 @default.
- W3160332462 creator A5030939217 @default.
- W3160332462 creator A5032130096 @default.
- W3160332462 creator A5032538718 @default.
- W3160332462 creator A5033466135 @default.
- W3160332462 creator A5038405725 @default.
- W3160332462 creator A5040273871 @default.
- W3160332462 creator A5040712332 @default.
- W3160332462 creator A5046453369 @default.
- W3160332462 creator A5047342267 @default.
- W3160332462 creator A5052403823 @default.
- W3160332462 creator A5054278844 @default.
- W3160332462 creator A5055783535 @default.
- W3160332462 creator A5056454945 @default.
- W3160332462 creator A5057605289 @default.
- W3160332462 creator A5060832273 @default.
- W3160332462 creator A5067539900 @default.
- W3160332462 creator A5079676682 @default.
- W3160332462 creator A5084227403 @default.
- W3160332462 creator A5086869616 @default.
- W3160332462 creator A5088331391 @default.
- W3160332462 date "2021-05-12" @default.
- W3160332462 modified "2023-10-18" @default.
- W3160332462 title "Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study" @default.
- W3160332462 cites W1600041372 @default.
- W3160332462 cites W2036193982 @default.
- W3160332462 cites W2126049444 @default.
- W3160332462 cites W2141231045 @default.
- W3160332462 cites W2795939598 @default.
- W3160332462 cites W3009799538 @default.
- W3160332462 cites W3013302817 @default.
- W3160332462 cites W3013871850 @default.
- W3160332462 cites W3015530221 @default.
- W3160332462 cites W3016572296 @default.
- W3160332462 cites W3017545174 @default.
- W3160332462 cites W3019445414 @default.
- W3160332462 cites W3023640683 @default.
- W3160332462 cites W3023751598 @default.
- W3160332462 cites W3025099648 @default.
- W3160332462 cites W3028967077 @default.
- W3160332462 cites W3034078474 @default.
- W3160332462 cites W3034110780 @default.
- W3160332462 cites W3036826034 @default.
- W3160332462 cites W3038176257 @default.
- W3160332462 cites W3038411417 @default.
- W3160332462 cites W3043851305 @default.
- W3160332462 cites W3047855637 @default.
- W3160332462 cites W3048657604 @default.
- W3160332462 cites W3086301763 @default.
- W3160332462 cites W3089258048 @default.
- W3160332462 cites W3089335552 @default.
- W3160332462 cites W3090456748 @default.
- W3160332462 cites W3090636667 @default.
- W3160332462 cites W3097009252 @default.
- W3160332462 cites W3118396415 @default.
- W3160332462 cites W3122900688 @default.
- W3160332462 cites W4253393964 @default.
- W3160332462 doi "https://doi.org/10.1186/s12916-021-01992-9" @default.
- W3160332462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8114973" @default.
- W3160332462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33980231" @default.
- W3160332462 hasPublicationYear "2021" @default.
- W3160332462 type Work @default.
- W3160332462 sameAs 3160332462 @default.
- W3160332462 citedByCount "11" @default.
- W3160332462 countsByYear W31603324622021 @default.
- W3160332462 countsByYear W31603324622022 @default.
- W3160332462 countsByYear W31603324622023 @default.
- W3160332462 crossrefType "journal-article" @default.
- W3160332462 hasAuthorship W3160332462A5000143586 @default.
- W3160332462 hasAuthorship W3160332462A5001965211 @default.
- W3160332462 hasAuthorship W3160332462A5004792362 @default.
- W3160332462 hasAuthorship W3160332462A5008912002 @default.
- W3160332462 hasAuthorship W3160332462A5010358276 @default.
- W3160332462 hasAuthorship W3160332462A5012387973 @default.
- W3160332462 hasAuthorship W3160332462A5013366022 @default.
- W3160332462 hasAuthorship W3160332462A5019430299 @default.
- W3160332462 hasAuthorship W3160332462A5021414030 @default.
- W3160332462 hasAuthorship W3160332462A5021832421 @default.
- W3160332462 hasAuthorship W3160332462A5022630756 @default.
- W3160332462 hasAuthorship W3160332462A5024457860 @default.
- W3160332462 hasAuthorship W3160332462A5026681178 @default.
- W3160332462 hasAuthorship W3160332462A5030324301 @default.
- W3160332462 hasAuthorship W3160332462A5030939217 @default.
- W3160332462 hasAuthorship W3160332462A5032130096 @default.
- W3160332462 hasAuthorship W3160332462A5032538718 @default.